When $EYPT published topline results for its LUGANO Phase 3 trial this morning, the market didn't hesitate: shares plunged 68%, instantly wiping out the majority of its $1.3B market cap.
This isn't an unproven low-float ghost pump—it's a brutal fundamental repricing on 83 million shares of float. Out of 865 historical catalyst gap-downs exceeding 30%, 59% of them continue lower to close red on the day. Trying to catch a falling biotech knife without checking historical odds is just paying market tuition.